Clinicopathological Profile of Pure Neuroendocrine Neoplasms of the Esophagus: A South Indian Center Experience

Table 3

Treatment received and outcomes.

Stage	Number of patients (percentage)	Median overall survival (mOS)	Range of survival
Stage I		0	0
Stage II		43 m	18–60 m
Stage III		12.5 m	6–30 m
Stage II and stage III	; (46.5%)
(1) Upfront surgery		19.75 m	6–60 m
(THE/TTE Cth)
(2) NACT + surgery		16 m	14–18 m
(3) Cth/LAR; no Surgery		8.75 m	6–13 m
Stage IV	; (53.5%)
(1) Cisplatin + etoposide (G3)		6.5 m	1.5–32 m
(2) Octreotide LAR (G2)		16 m